Perjeta and Herceptin for colorectal cacner – pro
Interim data presented by Hurwitz et al shows that HER2-targeted therapy with pertuzumab + trastuzumab, a chemotherapy-free regimen, is active in heavily pretreated HER2-amplified/overexpressed mCRC. The ORR was 37.5%, responses were durable (median 11.1 months), and the CBR was 46.9%. There is as well as an ongoing comprative study by Pratap et al, but resutls are not available. It is promising treatment, but more studies need to be completed and published before it would stop being E/I.
Herbert Hurwitz et al,Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Journal of Clinical Oncology 35, no. 4_suppl (February 2017) 676-676.P
Kanwal Pratap Singh Raghav et al, A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613. ournal of Clinical Oncology 36, no. 15_suppl – published online before print.